GB2112380A - A pyrimidone salt and its preparation - Google Patents
A pyrimidone salt and its preparation Download PDFInfo
- Publication number
- GB2112380A GB2112380A GB08215404A GB8215404A GB2112380A GB 2112380 A GB2112380 A GB 2112380A GB 08215404 A GB08215404 A GB 08215404A GB 8215404 A GB8215404 A GB 8215404A GB 2112380 A GB2112380 A GB 2112380A
- Authority
- GB
- United Kingdom
- Prior art keywords
- methyl
- pyrimidone
- ethylamino
- imidazolylmethylthio
- benzodioxolyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title description 3
- 150000008318 pyrimidones Chemical class 0.000 title description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims abstract description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 15
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims abstract description 10
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 9
- 239000012458 free base Substances 0.000 claims description 7
- -1 pyrimidone di(methanesulphonate) Chemical compound 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- 150000008081 1H-pyrimidin-4-ones Chemical class 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Air-Conditioning For Vehicles (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8116615 | 1981-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB2112380A true GB2112380A (en) | 1983-07-20 |
Family
ID=10522169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB08215404A Withdrawn GB2112380A (en) | 1981-05-30 | 1982-05-26 | A pyrimidone salt and its preparation |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4450161A (enExample) |
| EP (1) | EP0067579B1 (enExample) |
| JP (1) | JPS57206683A (enExample) |
| AT (1) | ATE9345T1 (enExample) |
| AU (1) | AU8431082A (enExample) |
| DE (1) | DE3260719D1 (enExample) |
| DK (1) | DK230482A (enExample) |
| ES (1) | ES8304094A1 (enExample) |
| GB (1) | GB2112380A (enExample) |
| GR (1) | GR76450B (enExample) |
| PT (1) | PT74958B (enExample) |
| ZA (1) | ZA823766B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230349922A1 (en) | 2020-08-11 | 2023-11-02 | Université De Strasbourg | H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4145546A (en) * | 1975-10-02 | 1979-03-20 | Smith Kline & French Laboratories Limited | 4-Pyrimidone compounds |
| IL57005A (en) * | 1978-04-11 | 1983-11-30 | Smith Kline French Lab | Process for the preparation of 2-amino pyrimid-4-one derivatives and novel 2-nitroaminopyrimid-4-ones as intermediates therefor |
| US4352933A (en) * | 1981-02-06 | 1982-10-05 | Smithkline Beckman Corporation | Chemical methods and intermediates for preparing substituted pyrimidinones |
-
1982
- 1982-05-21 DK DK230482A patent/DK230482A/da not_active Application Discontinuation
- 1982-05-25 JP JP57089611A patent/JPS57206683A/ja active Pending
- 1982-05-26 GB GB08215404A patent/GB2112380A/en not_active Withdrawn
- 1982-05-26 US US06/382,027 patent/US4450161A/en not_active Expired - Fee Related
- 1982-05-26 PT PT74958A patent/PT74958B/pt unknown
- 1982-05-27 DE DE8282302730T patent/DE3260719D1/de not_active Expired
- 1982-05-27 AT AT82302730T patent/ATE9345T1/de not_active IP Right Cessation
- 1982-05-27 EP EP82302730A patent/EP0067579B1/en not_active Expired
- 1982-05-27 GR GR68275A patent/GR76450B/el unknown
- 1982-05-28 ES ES512629A patent/ES8304094A1/es not_active Expired
- 1982-05-28 ZA ZA823766A patent/ZA823766B/xx unknown
- 1982-05-28 AU AU84310/82A patent/AU8431082A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK230482A (da) | 1982-12-01 |
| EP0067579A1 (en) | 1982-12-22 |
| EP0067579B1 (en) | 1984-09-12 |
| PT74958A (en) | 1982-06-01 |
| ZA823766B (en) | 1983-04-27 |
| DE3260719D1 (en) | 1984-10-18 |
| AU8431082A (en) | 1982-12-09 |
| ATE9345T1 (de) | 1984-09-15 |
| US4450161A (en) | 1984-05-22 |
| GR76450B (enExample) | 1984-08-10 |
| PT74958B (en) | 1983-12-23 |
| JPS57206683A (en) | 1982-12-18 |
| ES512629A0 (es) | 1983-02-16 |
| ES8304094A1 (es) | 1983-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW420612B (en) | Pharmaceutical composition for the treatment of HBV infection in a human or other host animal | |
| US3818035A (en) | 2{8 (2-ALKYLBENZO{8 b{9 {11 FURAN-3 yl)METHYL{9 -{66 {11 IMIDAZOLINE | |
| EP4652167A1 (en) | Glp-1r agonists and uses thereof | |
| JPS60228477A (ja) | ２‐アルコキシ‐ｎ‐（１‐アザビシクロ［２，２，２］オクト‐３‐イル）ベンズアミド類およびチオベンズアミド類 | |
| IE47798B1 (en) | Substituted ortho-anisamides,methods of preparing them,compositions containing them and their application as psychotropic agents | |
| KR20070050967A (ko) | 4-[[(7ｒ)-8-사이클로펜틸-7-에틸-5,6,7,8-테트라하이드로-5-메틸-4-6-옥소-2-프테리디닐]아미노]-3-메톡시-ｎ-(1-메틸-4-피페리디닐)벤즈아미드의 수화물 및 다형체, 이들의제조방법, 및 약제로서의 이들의 용도 | |
| KR910015562A (ko) | 뇌부전 질환치료용 약제, 신규 2-(1-피페라지닐)-4-페닐시클로알카노 피리미딘 유도체, 및 그의 제법 | |
| CN1387530A (zh) | 用作磷酸二酯酶vii抑制剂的咪唑并吡啶衍生物 | |
| RU2043994C1 (ru) | Глутатионалкиловые эфиры окисленного типа и способ их получения | |
| US20110136840A1 (en) | Anti-infective agents | |
| US5506264A (en) | Zinc tranexamate compounds | |
| US4877794A (en) | 2-Alkoxy-n-(1-azabicyclo(2.2.2)oct-3-yl) benzamide and thiobenzamide compositions and the use thereof to treat schizophrenia | |
| US4450161A (en) | Pyrimidone salt and its preparation | |
| GB1583691A (en) | Benzopyrans | |
| EP0397147B1 (en) | Stable solutions of rebeccamycin analog and preparation thereof | |
| JP4000397B2 (ja) | モルヒネ−６−グルクロニドの新しい結晶形熊 | |
| FI62311B (fi) | Foerfarande foer framstaellning av kristallint natrium- och kaiumcefalexinmonohydrat | |
| US3923996A (en) | 3-Substituted-oxindoles in compositions and methods of treating obesity | |
| AU704115B2 (en) | Zwitterionic forms of trovafloxacin | |
| JPH0572903B2 (enExample) | ||
| US4599346A (en) | Propan-2-ol derivatives, a process for their production and medicaments containing these compounds | |
| KR920006911B1 (ko) | 안정한 피록시캄 주사액 조성물 및 그의 제조방법 | |
| US5387597A (en) | Hemiphosphate hemihydrate of 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazole | |
| US6303608B1 (en) | 2-{4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]-1-piperazinyl}-5-fluoropyrimidine, its preparation and its therapeutic use | |
| EP0272849B1 (en) | Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |